Verrica Pharmaceuticals Inc. Operating Income

Quick Answer

Verrica Pharmaceuticals Inc. reported Operating Income of -$12.19 million for fiscal year 2025.

Verrica Pharmaceuticals Inc. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 -$12.19M +81.5%
2024 -$65.92M -0.2%
2023 -$65.76M -208.8%
2022 -$21.30M +31.1%
2021 -$30.91M +23.1%
2020 -$40.18M -33.6%
2019 -$30.08M -37.5%
2018 -$21.88M -390.9%
2017 -$4.46M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 $1.63M +107.9% +7.7%
June 30, 2025 $1.51M +109.9% +118.6%
March 31, 2025 -$8.13M +56.3% +60.7%
September 30, 2024 -$20.70M +13.4% -36.2%
June 30, 2024 -$15.21M -30.9% +18.2%
March 31, 2024 -$18.60M -162.4% +22.2%
September 30, 2023 -$23.92M -1751.7% -105.9%
June 30, 2023 -$11.62M -27.4% -63.9%
  • Verrica Pharmaceuticals Inc. showed an increase of +81.5% in Operating Income compared to the prior fiscal year.
  • Over the 2017–2025 period, Verrica Pharmaceuticals Inc.’s operating income has declined by 173.4% (from -$4.46 million to -$12.19 million).
  • The most recent figure is from Verrica Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment